Literature DB >> 23895654

The p53 miRNA interactome and its potential role in the cancer clinic.

Jonathan Krell1, Adam E Frampton, Teresa Colombo, Tamara M H Gall, Alex De Giorgio, Victoria Harding, Justin Stebbing, Leandro Castellano.   

Abstract

p53 is one of the most frequently mutated tumor suppressors. It regulates protein-coding genes and noncoding RNAs involved in many cellular processes, functioning predominantly at the transcriptional level but also through nontranscriptional processes. miRNAs have recently been identified as key mediators of the p53 stress-response pathway. p53 regulates miRNA transcription and processing, and miRNAs regulate p53 activity and expression and, accordingly, various feedback/feed-forward loops have been identified. Many chemotherapeutic agents induce cancer cell death or senescence via DNA damage and the subsequent activation of p53. Resistance to chemotherapy can occur due to the mutation of components in p53 signaling networks. A better understanding of the role of the various components within these pathways and their interactions with each other may allow the modification and improvement of current treatments, and the design of novel therapies. Improving our knowledge of the role of miRNAs in such p53 signaling networks may be crucial to achieving this.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23895654     DOI: 10.2217/epi.13.41

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  13 in total

Review 1.  microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.

Authors:  Yonit Hoffman; Yitzhak Pilpel; Moshe Oren
Journal:  J Mol Cell Biol       Date:  2014-06       Impact factor: 6.216

2.  Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma.

Authors:  Yuan Wang; Lian-Shun Jia; Wen Yuan; Zhao Wu; Hai-Bo Wang; Tao Xu; Jing-Chuan Sun; Ke-Fu Cheng; Jian-Gang Shi
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

3.  Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Junfen Ma; Nan Li; Jimin Zhao; Jing Lu; Yanqiu Ma; Qinghua Zhu; Ziming Dong; Kangdong Liu; Liang Ming
Journal:  Oncol Lett       Date:  2017-04-21       Impact factor: 2.967

4.  MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.

Authors:  Yang Zhang; Liying Geng; Geoffrey Talmon; Jing Wang
Journal:  J Biol Chem       Date:  2015-01-23       Impact factor: 5.157

5.  Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.

Authors:  Dmitriy W Gutkin; Michael R Shurin; Mounia Alaoui El Azher; Galina V Shurin; Liudmila Velikokhatnaya; Denise Prosser; Namhee Shin; Francesmary Modugno; Paul Stemmer; Esther Elishaev; Anna Lokshin
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

6.  The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.

Authors:  Christina G Towers; Anna L Guarnieri; Doug S Micalizzi; J Chuck Harrell; Austin E Gillen; Jihye Kim; Chu-An Wang; Michael U J Oliphant; David J Drasin; Michelle A Guney; Peter Kabos; Carol A Sartorius; Aik-Choon Tan; Charles M Perou; Joaquin M Espinosa; Heide L Ford
Journal:  Nat Commun       Date:  2015-12-21       Impact factor: 14.919

7.  Systematic analysis of the p53-related microRNAs in breast cancer revealing their essential roles in the cell cycle.

Authors:  Enxiang Zhou; N A Hui; Min Shu; Baiping Wu; Jianlin Zhou
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

8.  Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma.

Authors:  Kate Huang; Lin Chen; Jiliang Zhang; Zhi Wu; Linhua Lan; Lu Wang; Bin Lu; Yongzhang Liu
Journal:  Oncol Lett       Date:  2014-07-11       Impact factor: 2.967

9.  Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.

Authors:  Yao Zhang; Ye Hu; Jing-Yuan Fang; Jie Xu
Journal:  Oncotarget       Date:  2016-03-08

10.  Loss-of-function screening to identify miRNAs involved in senescence: tumor suppressor activity of miRNA-335 and its new target CARF.

Authors:  Yue Yu; Ran Gao; Zeenia Kaul; Ling Li; Yoshio Kato; Zhenya Zhang; Joanna Groden; Sunil C Kaul; Renu Wadhwa
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.